Extracorporeal Photopheresis for GVHD: The Procedure, Repeated Visits and Response Assessment

The name extracorporeal photopheresis can suggest radiotherapy, a blood exchange or a one-time removal of harmful immunity. ECP is a specialized cell-processing treatment. Some of the patient's white blood cells are collected, exposed outside the body to a light-sensitive medicine and ultraviolet light, and returned. The procedure requires suitable equipment, access and trained staff; it does not irradiate a lesion inside the body.

Key takeaways

These excerpts come from the original article. Read the full sections below for context.

The cells returned during ECP come from the patient. The aim is to modify immune activity associated with the disease. This differs from replacing the person's blood with donor blood or performing another hematopoietic stem-cell transplant. Describing it as a process that completely cleans the immune system would overstate what the procedure does.[1,2]
ECP commonly involves repeated procedures. The schedule varies with the disease setting, center and response, and chronic GVHD assessment may extend over a substantial period. A fixed cycle described in one hospital's information is an example of that service's approach, not a prescription for every patient.[2,5]
The sources reviewed did not provide patient-specific confirmation that a particular Chinese hospital can accept an overseas patient for ECP or provide the required course. Availability should therefore be confirmed directly. Use the full procedure name, extracorporeal photopheresis, together with the ECP abbreviation and the Chinese term 体外光分离治疗. Supply the GVHD type, affected organs, previous therapies and access details to avoid confusion with skin phototherapy or general blood purification.

Quick answer

Full guide

For someone considering a consultation in China, the first questions are whether ECP fits the current GVHD and whether assessment and treatment can continue reliably. Knowing that a facility has a machine does not establish a complete care plan. This guide describes the clinical and practical discussion, using sources checked through September 2026.

Treating cells outside the body still requires assessment of the whole patient

The cells returned during ECP come from the patient. The aim is to modify immune activity associated with the disease. This differs from replacing the person's blood with donor blood or performing another hematopoietic stem-cell transplant. Describing it as a process that completely cleans the immune system would overstate what the procedure does.[1,2]

Completion of a cell-processing session establishes that the treatment was delivered. It does not establish that GVHD is controlled. Clinical response must be assessed in the affected skin, mouth, liver, lungs or other organs. Machine time and clinical benefit are different measurements.

A useful initial plan therefore identifies the manifestations being targeted, the review points and the response to progression. A technical explanation alone leaves the patient without the information needed to decide whether the commitment is reasonable. Ask the team to connect the procedure to specific clinical goals.

When ECP may be considered

European specialist guidance includes ECP among options for selected steroid-refractory, steroid-dependent or steroid-intolerant chronic GVHD and discusses its use in acute GVHD. Recommendation depends on the affected organs, preceding treatment and ability to tolerate the process. It is not a routine requirement for every person after transplantation.[2]

The publication date of guidance matters. The 2026 ASTCT acute GVHD guideline identifies ruxolitinib as standard second-line treatment for steroid-refractory acute disease. Historical statements in older ECP papers that no medicines had been approved should not be presented as the current situation or used to require ECP before other established treatment.[3]

If ECP is recommended, ask whether the main reason is inadequate disease control, toxicity from existing treatment, difficulty tapering steroids or a particular organ problem. Those reasons may lead to different expectations and different decisions about accompanying medicines.

Assessment includes vascular access and overall stability

The service assesses veins or an existing access device, blood counts and the patient's condition before proceeding. Peripheral access is possible for some people; others need an appropriate longer-term device. A central catheter already in place is not automatically suitable for every collection system. The procedural team must confirm its type and function.[4]

Report recent infection, fever, bleeding, unstable blood pressure and previous reactions to photosensitizing or anticoagulant medicines. Children, smaller patients and people with limited physiological reserve may need different arrangements from a typical adult session. Individual assessment determines any additional preparation.[2]

Practical difficulties also deserve attention. Anxiety about needles, inability to remain in one position or frequent need for the bathroom may affect the experience. Raising them in advance allows the team to plan nursing support. These concerns should not be hidden out of fear of appearing uncooperative.

The treatment visit involves more than cell collection

Appropriate observations are taken around the procedure. Blood components pass through the collection system, the relevant cells are treated and returned, and anticoagulation helps prevent clotting in the circuit. The service selects the anticoagulant and technical arrangements. Patients do not need to memorize machine settings, but they should know that new discomfort can be reported immediately.[1,4]

The appointment may also involve laboratory work, waiting, access care and observation. A published estimate for machine time is not a guarantee of the total visit length. Avoid using it to schedule a tightly timed flight or long journey immediately afterward. Early sessions are a good opportunity to allow more flexibility and establish whether someone should accompany the patient home.

Wear clothing that allows access to the relevant arm or line. Tell staff about painful skin, restricted joints or respiratory symptoms that make positioning difficult. Necessary aids and the current medicine list should be available. Planning these details can make repeated attendance less demanding.

Prepare food, fluids and medicines according to personal instructions

Some services ask patients to avoid high-fat meals before ECP because lipids can interfere with cell separation. The performing center should provide its instructions. Intestinal GVHD, poor nutrition or a prescribed dietary restriction should be disclosed so that preparation fits the patient. Prolonged self-imposed fasting is not a substitute for that advice.[1,5]

Hospital leaflets may also contain instructions about blood-pressure medicines, diuretics or hydration that apply to their own service. These should not be converted into universal instructions for people with different cardiac, renal or blood-pressure problems. Confirm the day's medication plan with the prescribing team and keep a written version.

Contact the service if fever or significant deterioration develops before attendance. An appointment remaining on the calendar does not establish that the patient's current condition is suitable for treatment. The team may need to reassess before continuing.

The number of sessions is different from the time needed to judge benefit

ECP commonly involves repeated procedures. The schedule varies with the disease setting, center and response, and chronic GVHD assessment may extend over a substantial period. A fixed cycle described in one hospital's information is an example of that service's approach, not a prescription for every patient.[2,5]

Agree on the first formal response review and on which changes need earlier contact. Tissue tightness or restricted movement may improve gradually, but progression should not be dismissed indefinitely on the grounds that ECP can take time. Continuing, reducing frequency or changing treatment should remain active decisions based on the current findings.

A simple record of completed dates and changes in steroids or other immunosuppression helps interpretation. It gives the clinician the treatment context in which improvement occurred. Saying only that many sessions have been completed does not reveal whether accompanying medicines changed or whether all planned treatments were actually delivered.

Decide what would justify continuing

Response should be assessed with appropriate GVHD organ measures, rather than how the patient feels for a few hours after a session. NIH chronic GVHD response guidance distinguishes individual-organ change from overall response and accounts for progression in other sites. Symptoms, function and steroid burden are relevant, but should not be collapsed into an undefined statement that the procedure is working.[6]

For example, reduced skin redness and continuing inability to raise an arm can both be true. They describe different aspects of the condition. Falling lung function or new difficulty eating deserves assessment even if the skin looks better. Conversely, slow recovery of an established limitation does not automatically prove that current immune control has no value.

The team should explain why continuation is reasonable and which findings would alter that judgment. Patients should also describe fatigue, travel demands and financial burden. These are meaningful parts of shared decision-making, particularly when repeated visits affect work or caregiving responsibilities.

What the evidence can and cannot establish

A 2008 randomized study compared ECP plus standard therapy with standard therapy alone for cutaneous chronic GVHD. The primary endpoint, change in total skin score at week 12, did not show a statistically significant difference. Other assessments suggested benefit. A balanced account retains both observations rather than selecting favorable outcomes and describing a proven cure advantage.[7]

A 2024 single-center retrospective study included adults and children and also reported responses. The sample was small, and ECP was commonly given with other medicines. Such findings can inform practice without guaranteeing that another patient or another hospital will achieve the same result.[8]

Pulmonary chronic GVHD has its own guideline discussion of ECP and other options. The applicable population and certainty of evidence need separate interpretation. A response percentage from skin disease cannot become a probability of recovering lung function.[9] The individual target may involve improvement, stabilization or limiting further decline, and should be stated clearly.

Safety involves access, blood pressure and photosensitivity

Tell the staff promptly about dizziness, marked weakness, tingling around the lips, chest discomfort or other new symptoms during treatment. These changes need assessment rather than being endured until the machine finishes. A retained access device has separate care requirements, including attention to redness, pain, drainage and bleeding.[4,10]

The photosensitizing medicine increases skin and eye sensitivity to ultraviolet light for a period after treatment. The hospital should provide specific instructions for covering skin, sun protection and eye protection. Cloudy weather does not by itself remove the need to follow them.[4]

Some temporary symptoms can occur after a session, but fever after transplantation still requires the response agreed with the transplant team. It should not automatically be attributed to ECP. Existing immunosuppression and infection vulnerability do not disappear when this treatment begins.

Coordinate ECP with the medicines already prescribed

ECP may run alongside steroids or other immune-directed treatment. If control improves, the responsible team can discuss adjustments. Starting a procedure does not authorize stopping the previous oral regimen that day. The EBMT chronic GVHD chapter places organ care and systemic treatment within a broader management plan.[11]

Where different departments perform blood tests, provide prescriptions and deliver ECP, identify who reviews the combined information and makes treatment decisions. The procedural unit may not be responsible for all post-transplant prescribing. The patient needs a named route for overall clinical review, including between sessions.

Report medication changes made elsewhere so that the team can interpret both benefits and adverse events. A coherent record is especially useful when clinicians in two countries share care. Without it, a response may be attributed to ECP alone despite a major simultaneous change in another treatment.

Confirm continuing service before arranging treatment in China

The sources reviewed did not provide patient-specific confirmation that a particular Chinese hospital can accept an overseas patient for ECP or provide the required course. Availability should therefore be confirmed directly. Use the full procedure name, extracorporeal photopheresis, together with the ECP abbreviation and the Chinese term 体外光分离治疗. Supply the GVHD type, affected organs, previous therapies and access details to avoid confusion with skin phototherapy or general blood purification.

An RMB estimate should separate the initial assessment, line insertion or maintenance, each procedure, consumables, necessary tests and follow-up. Ask how many individual visits the quoted “cycle” contains. Until the review-dependent schedule is known, a total-course price cannot be reliable. Accommodation and transport should follow the actual clinical plan.

Continuation at home requires acceptance by the receiving service in advance. A note recommending ECP is not proof that a local unit can immediately deliver it. Transfer the completed treatment dates, tolerance, organ changes and accompanying prescriptions. Establishing this full period of care is essential to deciding whether traveling to China for ECP is practical for the individual patient.

References

MSK. Common Questions About Photopheresis: https://www.mskcc.org/cancer-care/patient-education/frequently-asked-questions-about-photopheresis
EDF. Photopheresis guidelines, part 1, 2020: https://pmc.ncbi.nlm.nih.gov/articles/PMC7820969/
ASTCT. Acute GVHD treatment guideline, 2026: https://pubmed.ncbi.nlm.nih.gov/42155643/
University Hospitals Birmingham. Photopheresis patient booklet: https://www.uhb.nhs.uk/media/susgbfzh/pi-haematology-photopheresis.pdf
Cambridge University Hospitals. ECP patient information: https://www.cuh.nhs.uk/patient-information/extra-corporeal-photopheresis-ecp/
NIH. Chronic GVHD response criteria: https://pmc.ncbi.nlm.nih.gov/articles/PMC4744804/
Flowers et al. Randomized phase II ECP study. Blood, 2008: https://pubmed.ncbi.nlm.nih.gov/18621929/
Ionete et al. Pediatric and adult ECP cohort, 2024: https://pubmed.ncbi.nlm.nih.gov/39274405/
ERS/EBMT. Adult pulmonary chronic GVHD guideline, 2024: https://publications.ersnet.org/lookup/pmid/38485149
MSK. Tunneled catheter care: https://www.mskcc.org/cancer-care/patient-education/about-your-tunneled-catheter
EBMT Handbook. Chronic Graft-Versus-Host Disease, 2024: https://www.ncbi.nlm.nih.gov/books/NBK608236/